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SUMMARY
We describe a 33-yr-old man suffering from severe vertebral osteoporosis and urticaria pigmentosa due to systemic mast cell
disease (SMCD). Because i.v. clodronate therapy could not prevent further vertebral fractures, an additional treatment with
interferon alpha-2b was initiated. During 24 months of treatment, our patient had no further pain episodes, no new vertebral
fractures were discovered, trabecular bone mineral density (BMD) increased significantly and urticarial symptoms improved.
Nevertheless, the extent of skin lesions remained unchanged. On histological examination, a remarkable decrease of mast cells
was observed in the bone marrow, but not in the skin. Five months after discontinuation of interferon alpha-2b, trabecular BMD
decreased and urticarial symptoms deteriorated. These findings illustrate a beneficial effect of interferon alpha-2b on
SMCD-induced osteoporosis as well as urticarial symptoms, and raise the question whether this treatment may have a diverse
impact on mast cell populations in different tissues.
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SYSTEMIC mast cell disease (SMCD) is an uncommon
disorder characterized by an abnormal proliferation of
mast cells with infiltration of skin, bone marrow,
spleen, liver and lymph nodes [1,2]. Typical symptoms
include flushing, diarrhoea, vomiting and a skin rash
called urticaria pigmentosa. In addition, bone pain,
radiographic bone lesions and generalized osteoporo-
sis, occasionally the only manifestation of SMCD, have
been described [3-11].
There is no cure for SMCD and prospects in the
treatment of SMCD-associated osteoporosis are poor
[11-15]. The bisphosphonate clodronate may have a
transient efficacy in reducing bone turnover [14] and
interferon alpha might be helpful in the treatment of
life-threatening SMCD [16, 17].
We report on a patient suffering from severe
vertebral osteoporosis and urticaria pigmentosa due to
SMCD. After i.v. clodronate therapy for 2 yr had failed
in every respect, we established additional injections of
interferon alpha-2b.
CASE REPORT
In February 1991, a diagnosis of SMCD with urticaria
pigmentosa and osteoporosis was made in a 33-yr-old man
with severe back pain.
The skin showed a widespread typical maculopapular rash
with Darier's sign and an intense urticarial reaction. On
biopsy, there was a perivascular mast cell infiltration in the
corium. Thoracic and lumbar spine radiographs revealed
fractures of most thoracic and lumbar vertebral bodies 4 and
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5. Mean lumbar trabecular bone mineral density (BMD) of
vertebral bodies 1-3, measured by single-energy quantitative
computed tomography, was 30.4 mg calcium hydroxyapatite
(Ca-HA)/ml, equivalent to 4.3 s.D. below the age- and
sex-related reference value [18]. A massive infiltration by mast
cells was found in a bone marrow aspirate specimen taken
from the posterior iliac crest. Histomorphometry of a
tetracycline double-labelled iliac bone biopsy revealed: (1)
reduced recruitment and/or life span of osteoblasts, as
indicated by decreased osteoblast surface; (2) diminished
synthetic activity of individual osteoblasts, deduced from the
marked decrease in osteoid volume, surface and thickness,
and confirmed by non-measurable bone formation rate; (3)
normal bone resorption (Table I) [19]. All blood tests for
other causes of osteoporosis, including cortisol, free
testosterone, intact parathormone, 25-hydroxyvitamin D3,
thyroid-stimulating hormone, growth hormone, calcitonin,
and urinary excretion of calcium and hydroxyproline, were
within normal limits. Urinary excretion of N-methylhis-
tamine was only slightly elevated and serum tryptase was
undetectable.
Treatment with clodronate
During i.v. treatment with clodronate, 600 mg every other
month, pain improved only temporarily. Urticarial symp-
toms and lesions remained unchanged with persistent
Darier's sign. After 2 yr, new fractures of lumbar vertebral
bodies 4 and 5 were noticed, and trabecular BMD was
slightly decreasing (Table II). Mast cell infiltration of the
bone marrow remained pronounced.
Treatment with interferon alpha-2b
In August 1993, additional treatment with s.c. injections of
interferon alpha-2b (Intron A*; Essex SA, Switzerland) was
initiated at a daily dose of 0.5 million U and increased every
3 weeks by 0.5 million U to a maximum of 5 million U/day.
In August 1994, the dose was reduced to 3 x 3 million
U/week.
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TABLE I
Historaorphometric parameters of bone formation
Histomorphometric parameters of
bone formation
Osteoid volume/total volume (%)
Osteoid surface/bone surface (%)
Osteoid thickness (jtm)
Osteoblast surface/bone surface (%)
Bone formation rate/bone surface
(//mJ//imJ/day)
WaU width (/*m)
Patient's
0.6
3.1
5.5
0.5
NM'
31.3
Normal values
data (mean ± S.D.)
4.9 (2.8)
11.6(6.0)
11.1 (2.5)
5.0 (3.2)
• 0.023 (0.018)
51.0 (5.6)
•Not measurable.
Urticarial symptoms decreased remarkably and Darier's
sign became negative 4 months after the introduction of
interferon alpha-2b. Skin lesions, however, were still present
to the same extent and pcrivascular mast cells in biopsy of
lesional skin even increased slightly after 12 months. The
patient had no further pain episodes and no new fractures
were discovered. Lumbar trabecular BMD increased
significantly within 1 yr and remained stable after dose
reduction of interferon (Table II). Bone marrow aspirate and
biopsy specimens showed a remarkable decrease of mast cells
after 6 months, and a further reduction after 12 months.
Side-effects
A dose reduction due to adverse effects of interferon
alpha-2b was never necessary. Quality of life in general was
good throughout the treatment, although a slight tendency to
depression, an increased need for sleep and a slight loss of
hair were reported, beginning at a daily dose of 3.5 million
U. These effects improved after a dose reduction to 3 x 3
million U/week. A mild myelosuppression of all three cell
lines was noted, starting at a daily dose of 3 million U and
resulting in minimal values for haemoglobin of 12.9 g/dl,
white blood cells of 3.0 x 10*/l and platelets of 127 x lO'/l at
a daily dose of 5 million U. All other laboratory parameters
did not change throughout the observation period.
Follow-up
Clodronate was stopped in January 1995 and interferon
alpha-2b in July 1995 due to well-being of the patient and
stable trabecular BMD. However, urticarial symptoms
deteriorated 1 month later and trabecular BMD decreased
significantly until December 1995 (Table II).
TABLE II
Trabecular bone mineral density (BMD). The Z-score is defined by
the number of standard deviations below the age- and sex-related
reference value. From February 1991 until January 1995, i.v.
clodronate infusions were given every other month. From August
1993 until July 1995, s.c. interferon alpha-2b injections were added
Date
February 1991
August 1991
February 1992
September 1992
April 1993
August 1993
December 1993
April 1994
August 1994
February 1995
December 1995
Trabecular
BMD
(mg Ca-HA/ml)
30.4
21.5
22.0
21.3
19.6
26.0
33.7
47.3
41.5
39.7
29.3
Z-score
- 4 . 3
- 4 . 6
- 4 . 6
- 4 . 5
- 4 . 9
- 4 . 6
- 4 . 3
- 3 . 8
- 4 . 0
-4 .1
- 4 . 4
Per cent
change
from baseline
+ 16.9
-17 .3
-15 .4
-18.1
-24.6
0
+ 29.6
+ 81.9
+ 59.6
+ 52.7
+ 12.7
DISCUSSION
To our knowledge, this is the first report on the
beneficial effect of interferon alpha-2b on SMCD-
associated osteoporosis.
SMCD is a clonal disorder derived from early
pluripotent stem cells of the bone marrow [2, 20] and
in some respect resembles myeloproliferative diseases
that respond to treatment with interferon alpha [21]. In
chronic myelogenous leukaemia, doses up to 9 million
U/day are administered, whereas in hairy cell
leukaemia 9 million U/week have proven to be
effective. In our patient, treated with increasing doses
up to 5 million U/day, a clinical and radiological effect
emerged after 4 months at a daily dose of 3 million U
and no worsening occurred after a dose reduction to
3 x 3 million U/week, suggesting that low doses might
be sufficient in the treatment of osteoporosis due to
SMCD.
In analogy to two other case reports [16, 22], we
noticed a marked decrease of mast cells in the bone
marrow, but in our patient this effect emerged without
concomitant treatment with corticosteroids. We are
well aware of the possibility of a sampling error due to
the fact that mast cells gather in clusters. Although
urticarial symptoms improved, lesional skin of our
patient showed a slight increase of mast cells,
confirming the finding of another report [23]. These
observations suggest that interferon alpha-2b inhibits
proliferation of mast cells in the bone marrow, whereas
it may merely interfere with mast cell activity in the
skin. Conclusions drawn from the change in cutaneous
symptoms, which are easily evaluated, thus cannot
necessarily be applied to the course of osteoporosis. As
laboratory parameters of bone metabolism did not
change during treatment, the bone process could only
be judged by measurement of trabecular BMD. This is
a considerable impediment in the assessment of
interferon's therapeutic efficacy in osteoporosis.
In summary, we document a beneficial effect of
interferon alpha-2b treatment in a patient suffering
from severe osteoporosis due to SMCD, a potentially
disabling disease, for which no other effective treatment
is known. More reports are needed to confirm our
finding. Whether the response to interferon alpha-2b is
dependent on the mast cell phenotype remains to be
assessed in further studies.
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